Clinicopathological Features and Survival Analysis in Molecular Subtypes of Muscle-Invasive Bladder Cancer.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
01 Apr 2023
Historique:
received: 28 02 2023
revised: 25 03 2023
accepted: 31 03 2023
medline: 14 4 2023
entrez: 13 4 2023
pubmed: 14 4 2023
Statut: epublish

Résumé

Molecular subtyping of bladder cancer (BC) aims to capture the biological heterogeneity of this complex disease in order to provide better patient risk stratification. Immunohistochemical (IHC) markers are regarded as promising surrogates to classify BCs into luminal and basal subtypes in routine practice. We investigated the correlation between the molecular subclassification, assessed through IHC, and the conventional prognostic variables of a cohort of 93 muscle-invasive BCs (MIBCs), with a focus on the pattern of muscularis propria (MP) invasion, and evaluated their association with outcome. Basal, luminal, double-positive (DP), and double-negative (DN) phenotypes were identified according to the coordinate expression of 1 basal (CK5/6) and 2 luminal (CK20, GATA3) markers, and accounted for 33.3%, 32.3%, 3.2%, and 31.2% (Scheme #1) and 9.7%, 60.2%, 26.9%, and 3.2% (Scheme #2). There was a significant association between the pattern of MP invasion and the molecular subtypes according to Scheme #2, in that all 8 basal and DN cases, as well as 83% of DP cases, had a non-infiltrative invasion pattern. No consistent differences were observed in terms of OS and CSS between the molecular subtypes obtained through surrogate IHC markers. In keeping with previous studies, we report the correlation between the identification of BC subtypes and the presence of morphological prognostic factors, supporting the need for a comprehensive pathological evaluation, including clinicopathological and molecular parameters, in order to improve the diagnosis and management of MIBC.

Identifiants

pubmed: 37047581
pii: ijms24076610
doi: 10.3390/ijms24076610
pmc: PMC10095107
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Minerva Urol Nefrol. 2013 Dec;65(4):225-34
pubmed: 24091476
Front Oncol. 2020 Feb 07;10:102
pubmed: 32117752
World J Urol. 2018 Feb;36(2):157-170
pubmed: 29147759
Cancers (Basel). 2021 Dec 12;13(24):
pubmed: 34944855
Histopathology. 2018 Nov;73(5):748-757
pubmed: 29947424
Curr Urol Rep. 2018 Nov 9;19(12):111
pubmed: 30414013
Crit Rev Clin Lab Sci. 2015;52(5):242-55
pubmed: 26053693
Sci Rep. 2018 Feb 27;8(1):3737
pubmed: 29487377
EBioMedicine. 2016 Oct;12:105-117
pubmed: 27612592
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5
pubmed: 24520177
Int J Mol Sci. 2022 Jul 15;23(14):
pubmed: 35887164
Virchows Arch. 2021 Sep;479(3):515-521
pubmed: 34218288
PLoS One. 2019 Aug 30;14(8):e0221785
pubmed: 31469885
Cent European J Urol. 2015;68(1):9-14
pubmed: 26029471
Eur Urol. 2020 Apr;77(4):420-433
pubmed: 31563503
Pathol Res Pract. 2019 Jun;215(6):152413
pubmed: 30987832
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Pathol Int. 2021 Mar;71(3):173-182
pubmed: 33503295
Am J Surg Pathol. 2000 Jul;24(7):980-7
pubmed: 10895820
J Pathol. 2019 Apr;247(5):563-573
pubmed: 30604486
Am J Pathol. 2013 Sep;183(3):681-91
pubmed: 23827819
J Immunoassay Immunochem. 2021 Nov 2;42(6):662-678
pubmed: 34106817
Int J Mol Sci. 2022 Jul 16;23(14):
pubmed: 35887192
Int J Mol Sci. 2018 Oct 30;19(11):
pubmed: 30380731
Cancer Rep (Hoboken). 2021 Apr;4(2):e1313
pubmed: 33538412
Investig Clin Urol. 2021 May;62(3):274-281
pubmed: 33943049
Histopathology. 2006 Oct;49(4):406-10
pubmed: 16978204
J Cell Mol Med. 2021 Aug;25(16):7890-7900
pubmed: 34184816
Virchows Arch. 2006 May;448(5):604-11
pubmed: 16525827
Int J Mol Sci. 2021 Jan 10;22(2):
pubmed: 33435173
Sci Rep. 2020 Jun 16;10(1):9743
pubmed: 32546765
Eur Urol. 2017 Oct;72(4):544-554
pubmed: 28390739
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
J Clin Pathol. 2022 Nov;75(11):766-771
pubmed: 34103388
Pathol Oncol Res. 2005;11(2):87-91
pubmed: 15999152
Histopathology. 2019 Dec;75(6):865-875
pubmed: 31348552

Auteurs

Francesca Sanguedolce (F)

Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.

Ugo Giovanni Falagario (UG)

Department of Urology and Renal Transplantation, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.

Magda Zanelli (M)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Andrea Palicelli (A)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Maurizio Zizzo (M)

Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Stefano Ascani (S)

Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy.

Simona Tortorella (S)

Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.

Vito Mancini (V)

Department of Urology and Renal Transplantation, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.

Angelo Cormio (A)

Urology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, Via Conca 71, 60126, Ancona, Italy.

Giuseppe Carrieri (G)

Department of Urology and Renal Transplantation, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.

Luigi Cormio (L)

Department of Urology and Renal Transplantation, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Department of Urology, Bonomo Teaching Hospital, 76123 Andria, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH